📢 𝗝𝗨𝗦𝗧 𝗜𝗡: Anthropic Partners With Six Life Sciences Firms to Accelerate AI-Powered Drug Development - $ANT $BMY 👉 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: ➤ 𝗔𝗻𝘁𝗵𝗿𝗼𝗽𝗶𝗰 partners with 𝟲 𝗹𝗶𝗳𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲𝘀 organizations to test Claude. ➤ Partners include 𝗕𝗿𝗶𝘀𝘁𝗼𝗹 𝗠𝘆𝗲𝗿𝘀 𝗦𝗾𝘂𝗶𝗯𝗯, 𝗕𝗶𝗴𝗛𝗮𝘁, 𝗘𝗻𝘃𝗲𝗱𝗮, 𝗗𝗶𝘃𝗲𝗿𝗴𝗲𝗻𝗰𝗲, 𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗲, and 𝗧𝗵𝗲 𝗖𝗼𝗹𝘂𝗺𝗻 𝗚𝗿𝗼𝘂𝗽. ➤ 𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗲 𝗕𝗶𝗼𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀 designed a 𝟳𝟬% 𝘀𝗵𝗼𝗿𝘁𝗲𝗿 CAR T-cell component using Claude. ➤ Modified design produced approximately 𝟭𝟬𝘅 𝗺𝗼𝗿𝗲 cancer-targeting receptors in lab tests. ➤ 𝗗𝗶𝘃𝗲𝗿𝗴𝗲𝗻𝗰𝗲 𝗟𝗮𝗯𝘀 generated approximately 𝟯𝟱,𝟬𝟬𝟬 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗱𝗲𝘀𝗶𝗴𝗻𝘀 in one month. ➤ 𝗘𝗻𝘃𝗲𝗱𝗮 used Claude to review 𝟭,𝟬𝟲𝟭 𝗽𝗮𝗴𝗲𝘀 of manufacturing documentation. ➤ Claude identified 𝟭𝟭 𝗸𝗻𝗼𝘄𝗻 𝗶𝘀𝘀𝘂𝗲𝘀 plus 𝟳 𝗮𝗱𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹 𝗶𝘀𝘀𝘂𝗲𝘀, reducing review time 𝟴𝟵%. ➤ Claude drafted a regulatory document in 𝟰 𝗵𝗼𝘂𝗿𝘀 versus approximately 𝟯 𝗺𝗼𝗻𝘁𝗵𝘀. ➤ 𝗕𝗿𝗶𝘀𝘁𝗼𝗹 𝗠𝘆𝗲𝗿𝘀 𝗦𝗾𝘂𝗶𝗯𝗯 uses Claude for clinical trial planning and success estimates. ➤ Anthropic acquired 𝗠𝗶𝘁𝗵𝗿𝗶𝗹 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲 and launched 𝗖𝗹𝗮𝘂𝗱𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲. 👉 𝗪𝗵𝘆 𝗧𝗵𝗶𝘀 𝗠𝗮𝘁𝘁𝗲𝗿𝘀: ➤ Demonstrates AI's potential to 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 and reduce development costs. ➤ Significant efficiency gains could transform 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 and regulatory workflows. ➤ Partnerships position 𝗔𝗻𝘁𝗵𝗿𝗼𝗽𝗶𝗰 to expand into the high-value 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗔𝗜 market. ➤ 𝗕𝗿𝗶𝘀𝘁𝗼𝗹 𝗠𝘆𝗲𝗿𝘀 𝗦𝗾𝘂𝗶𝗯𝗯 (𝗕𝗠𝗬) gains AI-assisted clinical development capabilities. ➤ Early laboratory results remain preliminary and require 𝗳𝘂𝗿𝘁𝗵𝗲𝗿 𝘃𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻 before clinical use. 👉 𝗘𝘅𝗽𝗲𝗿𝘁 𝗦𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁: 𝗠𝗶𝗰𝗵𝗮𝗲𝗹 𝗣𝗼𝘂𝗿𝗱𝗲𝗵𝗻𝗮𝗱, Senior Vice President and Head of Early Clinical Development at Bristol Myers Squibb: "generated a robust initial analysis that helped inform our assessment of different development options, which would otherwise take days to complete."